News
Biosimilar Zirabev Gets FDA Approval for 5 Types of Cancer
The FDA has approved Zirabev (bevacizumab-bvzr; Pfizer), a biosimilar to Avastin (bevacizumab; Genentech).
Your search for bevacizumab returned 3 results
Generics News
Pfizer Announces Launch of Three Biosimilar Cancer Treatments
Pfizer announced the launch of 3 new biosimilars: Zirabev (bevacizumab-bvzr), Ruxience (rituximab-pvvr) and Trazimera (trastuzumab-qyyp). Zirabev, a biosimilar to Avastin (bevacizumab; Genentech), is available for the treatment of 5 types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent…
News
Mirvetuximab Soravtansine Data Lacking for FDA’s Accelerated Approval in Ovarian CA
The Food and Drug Administration (FDA) has recommended that ImmunoGen, Inc. conduct a new phase 3 randomized trial to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) in patients with high folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.
